These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36982913)

  • 21. Fruquintinib and its use in the treatment of metastatic colorectal cancer.
    Deng Y; Li X
    Future Oncol; 2019 Aug; 15(22):2571-2576. PubMed ID: 31407939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies.
    Wang L; Cao H; Jiang C; He W; You Y; Peng K; Jin Y; Xia L
    Front Oncol; 2020; 10():587692. PubMed ID: 33282739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.
    Lu S; Chen G; Sun Y; Sun S; Chang J; Yao Y; Chen Z; Ye F; Lu J; Shi J; He J; Liu X; Zhang Y; Liu Z; Fang J; Cheng Y; Hu C; Mao W; Hu Y; Gong Y; Shan L; Yang Z; Song Y; Li W; Bai C; Wang B; Ma R; Zheng Z; Liu M; Jie Z; Cao L; Liao W; Pan H; Huang D; Chen Y; Yang J; Qin S; Ma S; Liang L; Liu Z; Zhou J; Tao M; Huang Y; Qiu F; Huang Y; Guan S; Peng M; Su W
    Lung Cancer; 2020 Aug; 146():252-262. PubMed ID: 32592986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
    Nie C; Xu W; Chen B; Lv H; Wang J; Liu Y; He Y; Wang S; Zhao J; Chen X
    Clin Colorectal Cancer; 2023 Mar; 22(1):76-84. PubMed ID: 36564281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer.
    Zhang PF; Xie D; Li Q
    Tumori; 2020 Oct; 106(5):400-405. PubMed ID: 32354261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.
    Sun Q; Zhou J; Zhang Z; Guo M; Liang J; Zhou F; Long J; Zhang W; Yin F; Cai H; Yang H; Zhang W; Gu Y; Ni L; Sai Y; Cui Y; Zhang M; Hong M; Sun J; Yang Z; Qing W; Su W; Ren Y
    Cancer Biol Ther; 2014; 15(12):1635-45. PubMed ID: 25482937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer.
    Jin Y; Li J; Shen L; Xu J; Zhang Y; Zhang J; Pan H; Qu X; Chen Y; Zhang Q; Li J; Sun M; Qin S
    Front Oncol; 2022; 12():1044328. PubMed ID: 36505849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China.
    Gou M; Qian N; Zhang Y; Yan H; Si H; Wang Z; Dai G
    Front Oncol; 2022; 12():851756. PubMed ID: 35875064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study.
    Dai Y; Sun L; Zhuang L; Zhang M; Zou Y; Yuan X; Qiu H
    J Gastrointest Oncol; 2022 Apr; 13(2):722-731. PubMed ID: 35557597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer.
    Wang Y; Wei B; Gao J; Cai X; Xu L; Zhong H; Wang B; Sun Y; Guo W; Xu Q; Gu Y
    J Immunol; 2020 Nov; 205(10):2905-2915. PubMed ID: 33028620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.
    Lu S; Chang J; Liu X; Shi J; Lu Y; Li W; Yang JJ; Zhou J; Wang J; An T; Yang L; Liu Z; Zhou X; Chen M; Hua Y; Su W
    J Clin Oncol; 2018 Apr; 36(12):1207-1217. PubMed ID: 29528793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer.
    Martinez-Perez J; Riesco-Martinez MC; Garcia-Carbonero R
    Expert Opin Drug Saf; 2018 Jun; 17(6):643-650. PubMed ID: 29745737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
    Giuliani J
    Clin Colorectal Cancer; 2022 Jun; 21(2):e145-e147. PubMed ID: 34969632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Bullement A; Underhill S; Fougeray R; Hatswell AJ
    Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
    André T; Falcone A; Shparyk Y; Moiseenko F; Polo-Marques E; Csöszi T; Campos-Bragagnoli A; Liposits G; Chmielowska E; Aubel P; Martín L; Fougeray R; Amellal N; Saunders MP
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):133-144. PubMed ID: 36470291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
    Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
    Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
    Coutzac C; Trouilloud I; Artru P; Henriques J; Masson T; Doat S; Bouché O; Coriat R; Saint A; Moulin V; Vernerey D; Gallois C; De La Fouchardière C; Tougeron D; Taieb J
    Clin Colorectal Cancer; 2022 Jun; 21(2):132-140. PubMed ID: 35337742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
    Chan BM; Hochster HS; Lenz HJ
    Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer.
    Li J; Cai Y; Deng Y
    Curr Treat Options Oncol; 2021 Jun; 22(7):55. PubMed ID: 34097129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.